BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Monday, August 3, 2026
Home » Authors » Alfred Romann

Alfred Romann

Articles

ARTICLES

Innovation in India? Symmetrix launches phase II of targeted thrombolytic

Feb. 18, 2014
By Alfred Romann

HONG KONG – Regulators in India have approved phase II trials for the protein drug that targets blood clots and could help treat heart attack patients with fewer risks and side effects than existing treatments. It may be the first biopharmaceutical compound fully developed in the country.


Read More

Despite scandals, big pharma pullouts opportunity remains for biotechs in China

Feb. 12, 2014
By Cornelia Zou and Alfred Romann
HONG KONG – China remains an attractive and generally profitable market for biopharmaceutical companies with the right products.
Read More

Chinese New Year Predictions: Astrological horse brings marginal benefits to device stocks

Jan. 30, 2014
By Alfred Romann

Feng Shui masters bullish on markets for Year of the Horse, not so much for biopharma

Jan. 29, 2014
By Alfred Romann
SHANGHAI – Xin Chun Kuai Le! Kung Hei Fat Choi! The first is Mandarin for “Happy Spring Festival.” The second is the Cantonese equivalent of “Wishing you prosperity.”
Read More

Initial public offerings ban in China lifted, 2014 could be record year

Jan. 8, 2014
By Alfred Romann
HONG KONG – After a lost 2013, companies in China are expected to start issuing shares again this year and this could prove a boon to biopharmaceutical companies that are generally underrepresented in the markets in Shanghai and Shenzhen.
Read More
View All Articles by Alfred Romann

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for July 31, 2026.
  • Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors

    BioWorld Science
    Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
  • Silhouette illustration of DNA gene editing

    Death in Chinese gene-editing trial exposes ethical fault lines

    BioWorld
    The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
  • Mitochondria

    Seed funding at Adjuvia to treat mitochondrial dysfunction

    BioWorld Science
    Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
  • Skin through magnifier

    Replimune’s RP-1 for melanoma wins over FDA adcom

    BioWorld
    Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
    • Videos
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing